Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 141 to 150 of 1532

TitleReference numberPublishedLast updated
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Transition from children's to adults' servicesQS140
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Velmanase alfa for treating alpha-mannosidosisHST29
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Acne vulgaris: managementNG198
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934

Results per page

  1. 10
  2. 25
  3. 50
  4. All